[{"id":"a2c8942c-0a0f-498b-8a5e-e033d78eebcf","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008119","created_at":"2023-08-23T15:11:11.548Z","updated_at":"2024-07-02T16:35:39.252Z","phase":"Phase 3","brief_title":"Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer","source_id_and_acronym":"NCT06008119","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 11/24/2023","start_date":" 11/24/2023","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 12/24/2026","study_completion_date":" 12/24/2026","last_update_posted":"2023-08-23"},{"id":"df1aef8d-1125-430b-acad-455dcf473546","acronym":"","url":"https://clinicaltrials.gov/study/NCT06008106","created_at":"2023-08-23T15:11:11.269Z","updated_at":"2024-07-02T16:35:39.195Z","phase":"Phase 3","brief_title":"Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma","source_id_and_acronym":"NCT06008106","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • paclitaxel • temozolomide • dacarbazine • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 165","initiation":"Initiation: 09/22/2023","start_date":" 09/22/2023","primary_txt":" Primary completion: 09/22/2027","primary_completion_date":" 09/22/2027","study_txt":" Completion: 09/22/2027","study_completion_date":" 09/22/2027","last_update_posted":"2023-08-23"},{"id":"b5f5b451-b510-426e-bac7-2d14c444f59b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05900219","created_at":"2023-06-12T15:09:02.818Z","updated_at":"2024-07-02T16:35:45.895Z","phase":"Phase 2","brief_title":"Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study","source_id_and_acronym":"NCT05900219","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" PD-L1 • BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600","tags":["PD-L1 • BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/24/2023","start_date":" 09/24/2023","primary_txt":" Primary completion: 09/24/2025","primary_completion_date":" 09/24/2025","study_txt":" Completion: 09/24/2025","study_completion_date":" 09/24/2025","last_update_posted":"2023-06-12"},{"id":"1f4a51be-fa8d-4049-af4e-50e1fb9f34d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05233332","created_at":"2022-02-10T14:52:59.343Z","updated_at":"2024-07-02T16:35:46.766Z","phase":"Phase 2","brief_title":"Study of HL-085 and Vemurafinib in Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT05233332","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 186","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 01/20/2024","primary_completion_date":" 01/20/2024","study_txt":" Completion: 07/20/2024","study_completion_date":" 07/20/2024","last_update_posted":"2023-05-31"},{"id":"2e9c47f2-4cd8-4fc4-bb34-ab7a99f8abdd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05263453","created_at":"2022-03-02T16:52:42.865Z","updated_at":"2024-07-02T16:35:46.842Z","phase":"Phase 2","brief_title":"HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation","source_id_and_acronym":"NCT05263453","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K • BRAF V600E + BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 104","initiation":"Initiation: 09/06/2021","start_date":" 09/06/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-05-31"},{"id":"395f67cd-671d-4041-abf3-eb347b1ee42b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05217303","created_at":"2022-02-05T18:28:11.143Z","updated_at":"2024-07-02T16:35:46.778Z","phase":"Phase 2","brief_title":"HL-085 in NRAS-mutated Advanced Melanoma","source_id_and_acronym":"NCT05217303","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Completed","enrollment":" Enrollment 100","initiation":"Initiation: 11/02/2020","start_date":" 11/02/2020","primary_txt":" Primary completion: 02/19/2023","primary_completion_date":" 02/19/2023","study_txt":" Completion: 02/20/2023","study_completion_date":" 02/20/2023","last_update_posted":"2023-05-31"},{"id":"79812039-10e9-461b-948a-802649275a7a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05331105","created_at":"2022-04-15T11:53:16.673Z","updated_at":"2024-07-02T16:35:46.830Z","phase":"Phase 2","brief_title":"HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas","source_id_and_acronym":"NCT05331105","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/18/2021","start_date":" 10/18/2021","primary_txt":" Primary completion: 10/30/2025","primary_completion_date":" 10/30/2025","study_txt":" Completion: 10/31/2028","study_completion_date":" 10/31/2028","last_update_posted":"2023-05-31"},{"id":"95b8e7e2-e4e3-46d3-bc40-10cb1c4e56cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03973151","created_at":"2021-01-17T17:54:22.805Z","updated_at":"2024-07-02T16:35:46.786Z","phase":"Phase 1/2","brief_title":"Study of HL-085 in NRAS Mutant Advanced Melanoma","source_id_and_acronym":"NCT03973151","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" NRAS","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kolupin (tunlametinib)"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 09/01/2017","start_date":" 09/01/2017","primary_txt":" Primary completion: 01/18/2021","primary_completion_date":" 01/18/2021","study_txt":" Completion: 01/18/2021","study_completion_date":" 01/18/2021","last_update_posted":"2023-05-31"},{"id":"d7c92316-5deb-4e26-acda-421b37ed17fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03781219","created_at":"2021-01-18T18:42:05.306Z","updated_at":"2024-07-02T16:35:46.774Z","phase":"Phase 1","brief_title":"A PhaseI Study of HL-085 Plus Vemurafenib in Solid Tumor With BRAF V600 Mutation","source_id_and_acronym":"NCT03781219","lead_sponsor":"Shanghai Kechow Pharma, Inc.","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zelboraf (vemurafenib) • Kolupin (tunlametinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 07/01/2018","start_date":" 07/01/2018","primary_txt":" Primary completion: 12/01/2023","primary_completion_date":" 12/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2023-05-31"}]